new_0222_0469|RXDX|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment|price_next_month|price_second_month
new_0222_0469|RXDX|1|Prometheus Biosciences Inc Total Current Assets (Quarterly) (USD)|Prometheus Biosciences Inc Cash and Short Term Investments (Quarterly) (USD)|Prometheus Biosciences Inc Inventories (Quarterly) (USD)|Prometheus Biosciences Inc Net PP&E (Quarterly) (USD)|Prometheus Biosciences Inc Goodwill and Intangibles (Quarterly) (USD)|Prometheus Biosciences Inc Total Liabilities (Quarterly) (USD)|Prometheus Biosciences Inc Total Current Liabilities (Quarterly) (USD)|Prometheus Biosciences Inc Total Long Term Liabilities (Quarterly) (USD)|Prometheus Biosciences Inc Total Deposits (Quarterly) (USD)|Prometheus Biosciences Inc Book Value (Quarterly) (USD)|Prometheus Biosciences Inc Retained Earnings (Quarterly) (USD)|Prometheus Biosciences Inc Treasury Stock (Quarterly) (USD)|Prometheus Biosciences Inc EV to Revenues|Prometheus Biosciences Inc EV to Earnings|Prometheus Biosciences Inc EV to Free Cash Flow|Prometheus Biosciences Inc EV to Assets (Quarterly)|Prometheus Biosciences Inc PS Ratio|Prometheus Biosciences Inc PE Ratio|Prometheus Biosciences Inc Price to Book Value|Prometheus Biosciences Inc PEG Ratio|Prometheus Biosciences Inc Debt to Equity Ratio|Prometheus Biosciences Inc Dividend Yield|Prometheus Biosciences Inc Shareholder Yield (TTM)|Prometheus Biosciences Inc Percent of Shares Outstanding Short|Prometheus Biosciences Inc Total Receivables (Quarterly) (USD)|Prometheus Biosciences Inc Total Payables (Quarterly) (USD)|Prometheus Biosciences Inc Total Capital Stock (Quarterly) (USD)|Prometheus Biosciences Inc Return on Invested Capital|Prometheus Biosciences Inc Quality Ratio Score|Prometheus Biosciences Inc Momentum Score|Prometheus Biosciences Inc Beta (1Y)|Prometheus Biosciences Inc Sustainable Growth Rate (TTM)|Prometheus Biosciences Inc Institutional Investor Ownership Percentage|Prometheus Biosciences Inc Average Diluted Shares Outstanding (Quarterly)|Prometheus Biosciences Inc Total Employees (Annual)|Prometheus Biosciences Inc EPS Diluted (Quarterly) (USD)|Prometheus Biosciences Inc SG&A Expense (Quarterly) (USD)|Prometheus Biosciences Inc Shares Outstanding|Prometheus Biosciences Inc Repurchase of Capital Stock (Quarterly) (USD)|Prometheus Biosciences Inc Ordinary Shares Number (Quarterly)|Prometheus Biosciences Inc Payout Ratio|Prometheus Biosciences Inc Quick Ratio (Quarterly)|Prometheus Biosciences Inc Normalized Diluted EPS (Quarterly) (USD)|Prometheus Biosciences Inc Stock Buybacks (Quarterly) (USD)|Prometheus Biosciences Inc Effective Tax Rate (TTM)|Prometheus Biosciences Inc Return on Equity|Prometheus Biosciences Inc Net Income (TTM) (USD)|Prometheus Biosciences Inc Revenue (TTM) (USD)|Prometheus Biosciences Inc Dividend Per Share (Quarterly) (USD)|Prometheus Biosciences Inc Revenue (Quarterly) (USD)|Prometheus Biosciences Inc Gross Profit (Quarterly) (USD)|Prometheus Biosciences Inc Pre-Tax Income (Quarterly) (USD)|Prometheus Biosciences Inc Net Income (Quarterly) (USD)|Prometheus Biosciences Inc Net Interest Income (Quarterly) (USD)|Prometheus Biosciences Inc Price (USD)|Prometheus Biosciences Inc Total Return Price (USD)|Prometheus Biosciences Inc Enterprise Value (USD)|Prometheus Biosciences Inc 30-Day Average Daily Volume|Prometheus Biosciences Inc 1 Year Price Returns (Daily)|Prometheus Biosciences Inc Short Interest|Prometheus Biosciences Inc PE Ratio (Forward)|Prometheus Biosciences Inc PE Ratio (Forward 1y)|Prometheus Biosciences Inc PS Ratio (Forward)|Prometheus Biosciences Inc PS Ratio (Forward 1y)|Prometheus Biosciences Inc Quarterly EPS Estimates (USD)|Prometheus Biosciences Inc Quarterly Revenue Estimates (USD)|Prometheus Biosciences Inc Quarterly EPS Surprise|Prometheus Biosciences Inc Quarterly Revenue Surprise|Prometheus Biosciences Inc Quarterly Actual EPS (USD)|Prometheus Biosciences Inc Quarterly Actual Revenue (USD)|Prometheus Biosciences Inc Revenue Estimates for Current Fiscal Year (USD)|Prometheus Biosciences Inc Revenue Estimates for Next Fiscal Year (USD)|Prometheus Biosciences Inc Price Target (USD)|Prometheus Biosciences Inc Consensus Recommendation|Prometheus Biosciences Inc Price Target Num Estimates|Prometheus Biosciences Inc EPS Estimates for Current Fiscal Year (USD)|Prometheus Biosciences Inc EPS Estimates for Next Fiscal Year (USD)|Prometheus Biosciences Inc Research and Development Expense (Quarterly) (USD)|Prometheus Biosciences Inc Reconciled Depreciation (Quarterly) (USD)|Prometheus Biosciences Inc Non-Operating Interest Expense (Quarterly) (USD)|Prometheus Biosciences Inc Land and Improvements (Quarterly) (USD)|Prometheus Biosciences Inc Buildings and Improvements (Quarterly) (USD)|Prometheus Biosciences Inc Other Properties (Quarterly) (USD)|Prometheus Biosciences Inc Machine, Furniture & Equipment (Quarterly) (USD)||
new_0222_0469|RXDX|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric||
new_0222_0469|RXDX|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|monthly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|quarterly|monthly|quarterly|quarterly|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|monthly|monthly|monthly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0469|RXDX|5|91|91||91||91|91|91||91|91||1.44117647059|91.5|1.44117647059|91.5|1.44117647059||1.44||91|1.44117647059|91.5|15.3333333333|91|91|91|92||||92|30.6|91.3333333333|30|91.3333333333|91.3333333333|30.625||91|91|91|91.3333333333|91.3333333333||92|91|91||91.3333333333||91.3333333333|91.3333333333|91.3333333333|1.44117647059|1.44117647059|1.44117647059|1.44019138756||15.3333333333|||1.44117647059|1.44117647059|91.4285714286|91.4285714286|91.5|91.5|91.5|91.5|18.4705882353|31.4|18.6470588235|12.68|18.6470588235|28.5454545455|28.5454545455|91.3333333333|91.3333333333|91.3333333333|||91|91||
new_0222_0469|RXDX|6|3|3||3||3|3|3||3|3||238|2|238|2|238||225||3|238|2|21|3|3|3|1||||1|10|6|1|6|6|8||3|3|3|6|6||1|3|3||6||6|6|6|238|238|238|209||21|||34|34|7|7|2|2|2|2|17|10|17|25|17|11|11|6|6|6|||3|3||
new_0222_0469|RXDX|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0469|RXDX|202003||||||||||||||||||||||||||||||||||26.9849||-0.4865|2.387||||||-0.2578|||||||0.228||-6.954|-13.128|-0.532||||||||||||||||||||||||4.265|0.022|0.534||||||
new_0222_0469|RXDX|202006||||||||||||||||||||||||||||||||||26.9849||-0.3128|1.81||||||-0.2648|||||||0.179||-7.151|-8.44|-0.592||||||||||||||||||||||||4.923|0.027|0.595||||||
new_0222_0469|RXDX|202009||||||||||||||||||||||||||||||||||26.9849||-0.2574|3.173||||||-0.2901|||||||0.359||-7.826|-6.947|-0.361||||||||||||||||||||||||4.652|0.03|0.364||||||
new_0222_0469|RXDX|202012|57.456|54.201||0.447||157.174|15.255|141.919||-97.541|-99.146||||||||||-0.0759||||1.086|7.763||||||||34.6073||-0.2492|3.719|||34.6073||3.6242|-0.2661||||-37.138|1.229||0.463||-9.208|-8.623|-0.632||||||||||||||||||||||||5.307|0.03|0.637|||0.572|0.024||
new_0222_0469|RXDX|202103|318.62|311.231||0.913||19.802|8.787|11.015||300.199|-113.091||229.4541|-10.646|-9.6015|1.2627|251.2332||2.3582||0.0245||-31.0202|0.71|0.973|2.315|0.004||||||92.1323|8.3389|36|-1.67|5.222|38.7697||38.7697||35.5302|-1.6574|-218.5|||-37.955|1.761||0.76||-13.945|-13.945|-0.64|18.26|18.26|404.0687|138631.3||275257|||||-0.355|0.1|-1.3239|660|-0.3597|0.76|0.5|0.5|32.25|1.25|4|-1.585|-1.82|7.758|0.039|0.658|||1.077|0.024|24.57|23.29
new_0222_0469|RXDX|202106|311.589|304.389||1.109||30.738|17.698|13.04||282.428|-132.09||344.2333|-13.5383|-18.8702|2.0973|349.9445||3.3771||0.0262||-23.0637|1.9098|0.217|2.483|0.004|-28.6926||||-30.0033||38.8139||-0.49|5.618|38.8351||38.8351||17.2113|-0.49|||-30.0033|-48.514|1.908||0.326||-18.999|-18.999|-0.153|24.56|24.56|656.7971|221471.3667||741657|||||-0.35|0.15|-40|117.3333|-0.49|0.326|1.025|1.4267|32.25|1.25|4|-2.5|-2.07|13.554|0.056|0.19|||1.329|0.024|20.97|21.82
new_0222_0469|RXDX|202109|287.108|279.116||1.362||26.838|15.093|11.745||262.1|-159.423||251.599|-9.33|-13.5135|2.2248|279.8069||3.5176||||-23.6997|3.0037|0.679|2.138|0.004|-35.8226||||-36.8851|79.5437|38.8484||-0.7|10.248|38.8845||38.8845||18.5381|-0.6857|||-36.8851|-68.9|2.555||1.006||-27.333|-27.333|0.014|23.71|23.71|642.8355|76227.5333||1167958|||||-0.635|0.3333|-8.5512|201.803|-0.6893|1.006|1.644|1.57|34.75|1.25|4|-2.3|-2.105|17.551|0.078|0.013|||1.66|0.024|31.86|29.7
new_0222_0469|RXDX|202112|||||||||||||493.362||-26.4986||466.6202||5.8743|||||4.0657|||||||||86.1835||||||||||||||||||||||39.54|39.54|1260.54|353019.5667||1583169|||849.4326|234.0461|-0.6575|0.6151|||||2.5975|1.8126|47.1429|1.2857|7|-3.015|-2.49||||||||35.93|42
new_0222_0469|RXDX|202203|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.59|0.4333||||||||||||||||||||
new_0222_0469|RXDX|202206|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.595|0.4333||||||||||||||||||||
new_0222_0469|RXDX|202209|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.595|0.4333||||||||||||||||||||
new_0222_0469|RXDX|202212|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.6|0.4333||||||||||||||||||||